Bioniche Obtains Exclusive U.S. Rights to Equine Reproductive Product from
CreoSalus

BELLEVILLE, ON, Nov. 30 /CNW/ - Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology driven Canadian biopharmaceutical company, today announced that it has signed an agreement with Thorn BioScience LLC, a subsidiary of CreoSalus, Inc. The agreement provides exclusive rights to Bioniche to market and distribute CreoSalus' SucroMate^TM Equine product in the U.S., with a first right of negotiation to expand the territory.

SucroMate^TM Equine was just registered in the U.S. by the U.S. Food and Drug Administration (FDA), one of only 8 new FDA-approved animal health drugs in 2010. It is a controlled release injectable of deslorelin acetate, used to time ovulation in horses and increasing the likelihood of conception during breeding. This is particularly valuable for thoroughbred horses where natural breeding is utilized, and it is also used in mares inseminated with fresh, cooled, and frozen semen.

"This product is a natural fit with the Bioniche Animal Health portfolio of reproductive products for large animals, including horses," said Jim Phillips, President of Bioniche Animal Health (global). "The Company sells a portfolio of equine products in the U.S. market, and SucroMate; ^TM Equine will be a welcome addition to our offerings to equine veterinarians. SucroMate™ Equine particularly fits with our equine mycobacterial cell wall product - Settle^TM - a fast-acting, intrauterine or intravenous endometritis therapy for broodmares."

CreoSalus Co-Founder, Barry Simon, DVM, said, "Over a decade of research and development has been devoted to develop a platform technology that delivers peptides on a sustained release. SucroMate^TM Equine is the first application of the technology. It delivers a stable, sterile, and consistent dosage of deslorelin for mare ovulation. FDA approval of SucroMate^TM Equine provides veterinarians and horse owners with confidence in breeding their mares. Horsemen will no longer need to rely on compounded products that may not meet specifications or work properly."

An estimated 250,000 to 300,000 mares are bred each year in the United States. Successful foaling is often a challenge due to mistimed breeding or to other health complications such as endometritis. Bioniche is pleased to offer registered products that help equine veterinarians address these challenges. SucroMate^TM Equine will be available for the start of the 2011 breeding season in February, 2011.

About CreoSalus, Inc.

CreoSalus, Inc. is a privately held Louisville, Kentucky-based life sciences company specializing in the development and manufacturing of finished drugs, fine chemicals, and human medical devices. The Company's three operating businesses all relating to peptides are Advanced ChemTech (fine chemicals), Occam Design (human medical devices) and Thorn BioScience (finished drugs). Thorn BioScience's products include FDA-approved SucroMate^TM Equine and SucroMate^TM Porcine (under development) that regulate the ovulation in mares and sows, respectively.

About Bioniche Life Sciences Inc.

Bioniche Life Sciences Inc. is a research-based, technology-driven Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary products for human and animal health markets worldwide. The fully-integrated company employs 214 skilled personnel and has three operating divisions: Human Health, Animal Health, and Food Safety. The Company's primary goal is to develop proprietary cancer therapies supported by revenues from marketed products in human and animal health. Bioniche has been named one of the Top 50 Best Small and Medium-Sized Employers in Canada for 2010. For more information, please visit www.Bioniche.com.

Except for historical information, this news release may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

%SEDAR: 00013159EF

For further information:

Jennifer Shea, Vice-President, Communications, Investor & Government Relations
Bioniche Life Sciences Inc.
Telephone: [phone]
Cell: [phone]
[email protected]